Proton Pump Inhibitors - Deprescribing and Risks

Key Points

• Do not deprescribe a PPI until the ongoing indication and GI-bleeding risk have been reviewed.
• Many patients can step down from twice-daily to once-daily therapy.
• Rebound acid hypersecretion can mimic relapse after discontinuation.
• A taper, on-demand plan, or direct stop can all be reasonable depending on the patient.
• Strong indications such as severe erosive disease or high GI-bleeding risk usually justify ongoing therapy.
• Observational long-term associations should be interpreted cautiously and not exaggerated.
• Alarm symptoms require diagnostic evaluation rather than indefinite empiric self-treatment.
• Reassess indication periodically because the appropriate duration changes over time.

Algorithm

1. Identify the original indication and whether it remains active.
2. Assess prior GI bleeding, ulcer, Barrett disease, erosive esophagitis, NSAID/antithrombotic exposure, and alarm symptoms.
3. If a strong indication persists, continue the lowest effective regimen.
4. If no ongoing indication exists, reduce dose/frequency or discontinue with rebound counseling.
5. Use temporary antacid/H2 support and lifestyle measures as appropriate.
6. Reassess persistent recurrent symptoms after the rebound period.
7. Investigate dysphagia, bleeding, anemia, weight loss, or persistent vomiting.
8. Review long-term indication and dose periodically.

Clinical Synopsis & Reasoning

PPIs irreversibly inhibit the gastric parietal-cell H+/K+ ATPase and are the most potent routine acid-suppressive medications. Their benefit is substantial for healing erosive esophagitis, treating peptic ulcer disease, protecting high-risk patients from NSAID or antithrombotic-associated bleeding, and preventing rebleeding after selected ulcer syndromes. The first deprescribing step is therefore to identify whether one of these strong indications persists.

A medication list often contains a PPI started during hospitalization for 'stress prophylaxis' and continued indefinitely. Other patients remain on twice-daily dosing after an acute esophagitis or ulcer has healed even though once-daily therapy would be adequate. Deprescribing can mean complete discontinuation, reducing twice daily to once daily, switching to on-demand use, or using an H2 blocker for intermittent symptoms.

Stopping abruptly after prolonged therapy can produce rebound acid hypersecretion for days to weeks, causing heartburn that patients interpret as recurrence of the original disease. Counseling about rebound and providing temporary antacid/H2 options improves success. A taper is reasonable but not mandatory for every patient; the best method depends on symptom history and patient preference.

Long-term PPI use has been associated observationally with enteric infections, hypomagnesemia, vitamin/mineral changes, kidney disease, fractures, and other outcomes. Causality is strongest for some adverse effects and much weaker for others. Fear generated by observational associations should not lead to withdrawal in a patient with a major GI-bleeding indication or severe erosive disease.

Treatment Strategy & Disposition

At medication review, document the original indication, current symptoms, endoscopy history, ulcer/H. pylori history, NSAID/aspirin/anticoagulant use, Barrett esophagus, and prior GI bleeding. Patients with severe erosive esophagitis, esophageal ulcer/stricture, Barrett-related indications, high bleeding risk, or ongoing ulcer prevention generally should not be deprescribed without gastroenterology review.

For a low-risk patient whose indication has resolved, step down to the lowest effective dose or stop. Explain rebound symptoms and offer short-term antacid, alginate, or H2 receptor antagonist if appropriate. Lifestyle measures such as weight reduction when indicated, avoiding late meals, elevating the head of bed for nocturnal reflux, and reducing individual dietary triggers can support symptom control.

If symptoms recur persistently after a reasonable rebound period, reassess the diagnosis. Alarm features such as dysphagia, GI bleeding, anemia, weight loss, recurrent vomiting, or new symptoms in a higher-risk patient can require endoscopy or another diagnostic pathway rather than simply restarting over-the-counter PPI indefinitely.

Monitor magnesium or B12 selectively in patients with additional risk factors rather than ordering broad surveillance for every long-term user. Test and treat H. pylori when indicated. Review continued need at least annually even when the PPI remains appropriate.

Epidemiology / Risk Factors

• PPIs are among the most commonly prescribed chronic medications.
• A substantial proportion of long-term prescriptions lack a documented current indication.
• Older adults often accumulate PPIs during hospitalization and transitions of care.
• Population-level overuse creates cost and medication-burden concerns even though individual drugs are generally well tolerated.

Investigations

Strong Indications

Pharmacology

Prognosis / Complications

• Appropriately indicated PPI therapy prevents ulcer recurrence and GI bleeding.
• Rebound symptoms after deprescribing usually improve with time.
• Unnecessary chronic therapy can be reduced successfully with structured follow-up.
• Patients with strong indications generally have a favorable benefit-risk balance for continued use.

Patient Education / Counseling

• Expect temporary heartburn after stopping a long-term PPI and use the agreed rescue plan rather than assuming the disease has permanently worsened.
• Seek care for trouble swallowing, vomiting blood, black stools, unexplained anemia, weight loss, or persistent vomiting.
• If aspirin, anticoagulants, or NSAIDs are prescribed, ask whether stomach protection is still needed before stopping the PPI.
• Use the lowest effective dose that controls the proven indication.
• Bring OTC acid-suppressive products into medication reviews because they can recreate chronic therapy without clinician awareness.

Notes

Deprescribing should improve care, not simply reduce pill count. If a PPI prevents recurrent bleeding in a high-risk patient, continuing it is a safer medication decision than stopping it because of a weak observational association.

When stopping an unnecessary PPI, warn about rebound in advance. Without that explanation, a predictable short-lived physiologic effect often becomes the reason the medication is restarted indefinitely.

References

1. AGA best practice advice on PPI use — Link
2. Deprescribing guidelines for PPIs — Link